Search

Displaying results 3961 - 3970 of 10000 in total
  1. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  2. Drug

    R411

    go.drugbank.com/drugs/DB05468
    Experimental

    R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. … It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7.

  3. Drug

    CoviGlobulin

    go.drugbank.com/drugs/DB15747
    Experimental

    The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones. … CoviGlobulin, a rabbit polyclonal antibody, was specifically designed as a potential therapy for COVID-19.

  4. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. … Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier

  5. Drug

    Uprifosbuvir

    go.drugbank.com/drugs/DB15206
    Investigational

    Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis … C Genotype (GT)1 and GT2 Infection (MK-3682-011)).

  6. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    major adverse cardiovascular events in at-risk adults treated with statins or with monoclonal antibody PCSK9 inhibitors added to statin therapy. … [L63795] Adverse reaction frequencies were similar to placebo and the drug carries no contraindications.

  7. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation

    Synonyms: myristoylated recombinant SCR1-3 of human complement reseptor type I
  8. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase … Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors.

  9. Drug

    Cocamidopropyl betaine

    go.drugbank.com/drugs/DB11350
    Approved

    Cocamidopropyl betaine is used as a foam booster in shampoos, emulsifying agent, thickener, antistatic agent and rarely an antiseptic agent. … Cocamidopropyl betaine is a mixture of closely related organic compounds derived from coconut oil and dimethylaminopropylamine that typically acts as an amphoteric surfactant in cosmetics and personal

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.